Table 3.

A summary of cancers and diseases in which expression of Slits and Robos are elevated.

Decreased expression level
Gene	Mode of silencing	Cancer type	References
Slit2	LOH, allelic deletion	63% of breast carcinoma, 35% of cervical carcinoma, and >60% of small lung carcinoma and mesothelioma	Shivapurkar et al. (1999a, 1999b) and Singh et al. (2007)
Slit2	Promoter hypermethylation	Breast carcinoma, nonsmall cell lung cancer, ovarian carcinoma, gliomas, hepatocellular carcinoma, colorectal carcinoma, and lymphocytic leukemia primary tumors	Dallol et al. (2005, 2003a, 2003b), Dunwell et al. (2009), Jin et al. (2009), Qiu et al. (2011), Sharma et al. (2007)
Slit2	Unknown	Corneal neovascularization	Han and Zhang (2010) and Wang et al. (2008)
Slit, 3	Promoter hypermethylation	41% of breast, 33% of colorectal, and 29% of glioma tumor cell lines and primary tumors	Dallol et al. (2005) and Dickinson et al. (2004)
Slit3	Unknown	Hepatocellular carcinoma	Avci et al. (2008)
Slit2	Promoter hypermethylation catalyzed by polycomb group member EZH2	Human prostate cancer samples	Yu et al. (2010)
Robo1	Gene deletion	Small-cell lung cancer cell line (U2020)	Xian et al. (2001)
Robo1	Promoter hypermethylation	19% of primary invasive breast cancer, 18% of clear cell renal cell cancer, and 4% primary nonsmall cell lung cancer	Dallol et al. (2002b)
Robol, 2	Promoter hypermethylation	Early dysplastic lesions of head and neck cancer	Ghosh et al. (2009)
Robo3	Promoter hypermethylation	Cervical cancer	Narayan et al. (2006)
Robo4	Unknown	Human breast tumor samples	Richardson et al. (2006)
Robo4	Unknown	Hepatocellular carcinoma	Avci et al. (2008)